HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review. | Canada Hyperbarics Skip to main content
Case Study Journal of clinical pharmacy and therapeutics 2020

HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review.

Gluvic Z, Obradovic M, Lackovic M, Samardzic V, Tica Jevtic J, Essack M, et al. — Journal of clinical pharmacy and therapeutics, 2020

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers presented a case report of a male diabetic patient with beta-thalassaemia and reviewed existing literature on HbA1C as a marker for glycaemic control in such patients.

What They Found

They found that standard HbA1C values were not sufficient for assessing diabetes control in a patient with thalassaemia, despite an unacceptable five-point glycaemic profile. After insulin therapy and hyperbaric oxygen for an ulcer, the patient showed improved glycaemic control and ulcer healing. The study suggests that in thalassaemia, HbA1C should be measured by a different method or simultaneously with fructosamine due to discrepancies.

What This Means for Canadian Patients

Canadian patients with diabetes and co-existing thalassaemia may require alternative or additional methods, such as fructosamine testing, to accurately monitor their blood sugar control. Relying solely on standard HbA1C measurements might lead to misinterpretations of glycaemic status and suboptimal diabetes management in this specific population.

Canadian Relevance

This study has no direct Canadian connection.

Study Limitations

As a case report, the findings may not be generalizable to all patients with diabetes and thalassaemia, and the study highlights the inherent limitation of standard HbA1C testing in this specific patient group.

Was this summary helpful?

Study Details

Study Type Case Study
Category Wound Care
Source Pubmed
PubMed ID 31736110
Year Published 2020
Journal Journal of clinical pharmacy and therapeutics
MeSH Terms Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Foot; Fructosamine; Glycated Hemoglobin; Humans; Hyperbaric Oxygenation; Hypoglycemic Agents; Insulin; Male; beta-Thalassemia

Cite This Study

Share

Find a Canadian Clinic Treating Wound Care

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.